ClinicalTrials.gg
CompletedNCT01623466ATI-CL21Updated Jan 23, 2018Results posted

Study to Evaluate Pharmacokinetics Profile, Wearability, and Safety of 2 Progestin-Only Patches

A Phase 1/2 interventional study of levonorgestrel in Healthy, sponsored by Agile Therapeutics. Completed. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-01-23.

Sponsored by Agile Therapeutics · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

Pharmacokinetics, safety and wearability in two size patches of AG890 over eight weeks will be evaluated.

Read the detailed description

To evaluate pharmacokinetic (PK) profile, patch wearability (adhesion and skin irritation), and safety of AG890-6.5 and AG890-12.5 TCDS.

02

Conditions studied

  • Healthy

Keywords

  • PK and Safety
03

In context

Lead sponsor

Agile Therapeutics is the lead sponsor of 8 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) greater than or equal to 18.
  • Willing to use a non-hormonal method of if of , or have already undergone previous bilateral tubal ligation or hysterectomy
  • Willing to refrain from excessive use of alcohol from 48 hours prior to patch application through completion of the study.

Exclusion criteria

Exclusion Criteria:

  • Known or suspected pregnancy
  • Lactating women
  • Status post-partum or post-abortion within a period of 2 months prior to the start of study medication
  • A cervical cytology smear of Papanicolaou (Pap) class III or greater or a Bethesda System report of low grade squamous intraepithelial lesions (SIL) or greater
  • Smoking
  • Hypertension (blood pressure >140 mm Hg systolic and/or >90 mm Hg diastolic)
  • Valvular heart disease with complications
  • (in women with ≥35 kg/m2) with findings
  • Diabetes Mellitus
  • History of headaches with focal neurological symptoms
  • Uncontrolled thyroid disorder
  • Sickle cell anemia
  • Current or history of clinically significant depression in the last year
  • Known disturbance of lipid metabolism
  • Acute or chronic hepatocellular disease with abnormal liver function
  • Hepatic adenoma or carcinoma
  • Cholestatic jaundice of pregnancy or jaundice with prior hormonal use
  • Plans for major surgery
  • History of or existing venous and arterial thrombotic and thromboembolic disorder, vascular disease, cerebral vascular, or coronary artery disease
  • Undiagnosed abnormal genital bleeding
  • Known or suspected breast carcinoma, endometrial carcinoma, or estrogen-dependent neoplasia
  • History or presence of dermal in response to topical applications (bandages, surgical tape, etc.)
  • Use of an injectable hormonal contraceptive within the past 10 months prior to the screening visit
  • Use of a contraceptive implant or hormone-medicated intrauterine device (IUD) within 1 month prior to the screening visit
  • Use of oral contraceptives or other sex hormones within 2 months prior to the screening visit
  • Chronic use of any medication that might interfere with the efficacy of hormone contraceptives (including barbiturates, bosentan, carbamazepine, felbamate, griseofulvin, oxcarbazepine, phenytoin, rifampin, St. John's Wort, topiramate, and protease inhibitors), OR use of these medications within the past 3 months prior to screening visit
  • A recent history (within prior 2 years ) of drug or alcohol abuse
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    AG890-6.5

    Evaluate levonorgestrel delivery in AG890-6.5

    Drug: levonorgestrel

  • Experimental
    AG890-12.5

    Evaluate levonorgestrel delivery in AG890-12.5

    Drug: levonorgestrel

Interventions

  • transdermal contraceptive delivery system

    Also known as: patch, transdermal contraceptive delivery system

06

What researchers measure

Primary outcomes

  1. Levonorgestrel Pharmacokinetic Profile

    The percentage of subjects with a minimal LNG level below pre-specified threshold of 175 pg/mL during the study.

    Time frame: 8 weeks

  2. Evaluation of Patch Adhesion

    Evaluation of worst patch adhesion score for each subject using a 5-point adhesion scale: 0: ≥90% adhered (no lift) 1. ≥75% adhered but \<90% (some edges showing lift) 2. ≥50% adhered but \<75% (half of system lifts off) 3. \<50% (\< half of system lifts off, but undetached) 4. patch completely detached

    Time frame: 8 weeks

  3. Evaluation of Irritation at Patch Application Site

    Self-reported worst skin irritation score at patch application site for each subject using a 4-point irritation scale: 0: None 1. Mild 2. Moderate 3. Severe

    Time frame: 8 weeks

  4. Evaluation of Itching at Patch Application Site

    Self-reported worst skin itching at patch application site by subject using a 4-point scale: 0. None 1. Mild 2. Moderate 3. Severe

    Time frame: 8 weeks

  5. Cycle Control

    Measurement of unscheduled bleeding/spotting days.

    Time frame: 8 weeks

07

Results

Posted Aug 28, 2017

Participant flow

Participant flow — Overall Study
MilestoneAG890-6.5AG890-12.5
Started1818
Completed1718
Not completed10

Outcome measures

PrimaryLevonorgestrel Pharmacokinetic Profile

The percentage of subjects with a minimal LNG level below pre-specified threshold of 175 pg/mL during the study.

Time frame:
8 weeks
Reported as:
Number · % of subjects below 175 pg/mL
Levonorgestrel Pharmacokinetic Profile
% of subjects below 175 pg/mLAG890-6.5AG890-12.5
Levonorgestrel Pharmacokinetic Profile10083.3
PrimaryEvaluation of Patch Adhesion

Evaluation of worst patch adhesion score for each subject using a 5-point adhesion scale: 0: ≥90% adhered (no lift) 1. ≥75% adhered but \<90% (some edges showing lift) 2. ≥50% adhered but \<75% (half of system lifts off) 3. \<50% (\< half of system lifts off, but undetached) 4. patch completely detached

Time frame:
8 weeks
Reported as:
Mean · Score on a scale
Evaluation of Patch Adhesion
Score on a scaleAG890-6.5AG890-12.5
Evaluation of Patch Adhesion0.41 ± 1.0040.78 ± 1.517
PrimaryEvaluation of Irritation at Patch Application Site

Self-reported worst skin irritation score at patch application site for each subject using a 4-point irritation scale: 0: None 1. Mild 2. Moderate 3. Severe

Time frame:
8 weeks
Reported as:
Mean · Score on a scale
Evaluation of Irritation at Patch Application Site
Score on a scaleAG890-6.5AG890-12.5
Evaluation of Irritation at Patch Application Site0.11 ± 0.4710.06 ± 0.236
PrimaryEvaluation of Itching at Patch Application Site

Self-reported worst skin itching at patch application site by subject using a 4-point scale: 0. None 1. Mild 2. Moderate 3. Severe

Time frame:
8 weeks
Reported as:
Mean · Score
Evaluation of Itching at Patch Application Site
ScoreAG890-6.5AG890-12.5
Evaluation of Itching at Patch Application Site0.33 ± 0.5940.39 ± 0.502
PrimaryCycle Control

Measurement of unscheduled bleeding/spotting days.

Time frame:
8 weeks
Reported as:
Mean · days
Cycle Control
daysAG890-6.5AG890-12.5
Cycle Control8.4 ± 4.818.3 ± 4.23

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AG890-6.50/18 (0%)0/18 (0%)11/18 (61.1%)
AG890-12.50/18 (0%)0/18 (0%)9/18 (50%)
Most frequent other events
Most frequent other events
EventAG890-6.5AG890-12.5
Nervous system disordersNervous system disorders9/185/18
Reproductive system ad breast disordersReproductive system and breast disorders3/185/18
Metabolism and nutrition disordersMetabolism and nutrition disorders2/182/18
Psychiatric disordersPsychiatric disorders1/182/18
Gastrointestinal DisordersGastrointestinal disorders1/181/18
Immune system disordersImmune system disorders1/180/18
Skin and subcutaneous tissue disordersSkin and subcutaneous tissue disorders1/180/18

Baseline characteristics

Safety population

Age, Categorical
Age, Categorical(Participants)AG890-6.5AG890-12.5Total
<=18 years000
Between 18 and 65 years181836
>=65 years000
Age, Continuous
Age, Continuous(years)AG890-6.5AG890-12.5Total
Mean29.83 ± 8.47334.94 ± 6.67332.39 ± 7.951
Sex: Female, Male
Sex: Female, Male(Participants)AG890-6.5AG890-12.5Total
Female181836
Male000
Region of Enrollment
Region of Enrollment(Participants)AG890-6.5AG890-12.5Total
United States181836
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2012 to primary completion in Sep 2012, 2 months.

Results were first posted in Aug 2017, 4 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2012
First posted
Jun 20, 2012
StartActual
Jul 2012
Primary completionActual
Sep 2012
CompletionActual
Sep 2012
Results first posted
Aug 28, 2017
Last update
Jan 23, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01623466
Lead sponsor
Agile Therapeutics
Responsible party
Sponsor
First posted
Jun 20, 2012
Start date
Jul 2012
Primary completion
Sep 2012
Completion
Sep 2012
Results posted
Aug 28, 2017
Last update
Jan 23, 2018

Study contacts

Elizabeth Garner, MD, PHD
study director · Agile Therapeutics

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levonorgestrel

Start the discussion